Last 7 days
-14.8%
Last 30 days
-27.9%
Last 90 days
-20.8%
Trailing 12 Months
-40.0%
Income Statement (Last 12 Months) | ||||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2021Q4 | 2020Q4 | |
Revenue | -47.8% | 1,941,000 | 3,716,000 | - | ||
Operating Expenses | 10.7% | 167,628,000 | 151,446,000 | 87,067,000 | - | - |
S&GA Expenses | 14.8% | 37,533,000 | 32,695,000 | 18,865,000 | - | - |
R&D Expenses | 9.6% | 130,095,000 | 118,751,000 | 68,202,000 | - | - |
Net Income | -6.6% | -157,387,000 | -147,639,000 | -120,314,000 | - | - |
Net Income Margin | -104.1% | -81.09 | -39.73 | - | - | - |
Free Cahsflow | -7.0% | -135,564,000 | -126,728,000 | - | - | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 0.9% | 679 | 673 | 324 | 349 | 384 |
Current Assets | 0.3% | 563 | 562 | 299 | 329 | 367 |
Cash Equivalents | -56.6% | 120 | 277 | 73.00 | 91.00 | 64.00 |
Net PPE | 23.9% | 19.00 | 15.00 | 12.00 | 11.00 | 7.00 |
Liabilities | 2.3% | 128 | 125 | 28.00 | 18.00 | 27.00 |
Current Liabilities | 20.9% | 35.00 | 29.00 | 26.00 | 15.00 | 22.00 |
Shareholder's Equity | 0.5% | 551 | 548 | 296 | 331 | 357 |
Retained Earnings | -13.6% | -344 | -303 | -257 | -217 | -186 |
Additional Paid-In Capital | 5.1% | 896 | 852 | 555 | 549 | 544 |
Accumulated Depreciation | 20.5% | 4.00 | 3.00 | 3.00 | 2.00 | - |
Shares Outstanding | 2.1% | 62.00 | 60.00 | 49.00 | 49.00 | 49.00 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -4.1% | -122 | -117 | -109 | -96.25 | -77.88 |
Share Based Compensation | 21.3% | 22.00 | 19.00 | 15.00 | 11.00 | 7.00 |
Cashflow From Investing | -249.5% | -155 | -44.63 | -201 | -190 | -239 |
Cashflow From Financing | 13.2% | 329 | 291 | 1.00 | 284 | 377 |
85.0%
85.0%
82.8%
Y-axis is the maximum loss one would have experienced if Verve Therapeutics was unfortunately bought at previous high price.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-02-28 | Voya Investment Management LLC | added | 3.45 | -248,919 | 347,081 | -% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | new | - | 77.00 | 77.00 | -% |
2023-02-16 | HARBOUR INVESTMENTS, INC. | new | - | 19,350 | 19,350 | -% |
2023-02-15 | MetLife Investment Management, LLC | unchanged | - | -370,500 | 477,500 | -% |
2023-02-15 | JANE STREET GROUP, LLC | new | - | 267,340 | 267,340 | -% |
2023-02-15 | McIlrath & Eck, LLC | unchanged | - | -1,549 | 1,451 | -% |
2023-02-15 | LAZARD ASSET MANAGEMENT LLC | reduced | -21.5 | -37,000 | 27,000 | -% |
2023-02-15 | NOMURA HOLDINGS INC | new | - | 634,000 | 634,000 | -% |
2023-02-15 | Metropolitan Life Insurance Co/NY | unchanged | - | -41,859 | 54,141 | -% |
2023-02-15 | Highlander Capital Management, LLC | unchanged | - | -7,000 | 10,000 | -% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 14, 2023 | singer james r | 8.1% | 5e+06 | SC 13G/A | |
Feb 14, 2023 | casdin capital, llc | 3.7% | 2,290,571 | SC 13G/A | |
Feb 13, 2023 | arch venture fund x, l.p. | - | 0 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 6.19% | 3,812,024 | SC 13G | |
Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
Feb 07, 2023 | state street corp | 7.26% | 4,471,049 | SC 13G | |
Feb 06, 2023 | wellington management group llp | 1.39% | 859,102 | SC 13G/A | |
Feb 14, 2022 | gv 2017, l.p. | 13.12% | 6,320,905 | SC 13G | |
Feb 14, 2022 | casdin capital, llc | 6.5% | 3,138,167 | SC 13G/A | |
Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 02, 2023 | 10-K | Annual Report | |
Mar 02, 2023 | 8-K | Current Report | |
Mar 02, 2023 | S-8 | Employee Benefits Plan | |
Feb 23, 2023 | 3 | Insider Trading | |
Feb 17, 2023 | 8-K | Current Report | |
Feb 16, 2023 | 4 | Insider Trading | |
Feb 16, 2023 | 4 | Insider Trading | |
Feb 16, 2023 | 4 | Insider Trading | |
Feb 16, 2023 | 4 | Insider Trading | |
Feb 16, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2022-12-14 | Bellinger Andrew | acquired | 103,320 | 2.87 | 36,000 | cso & cmo |
2022-12-01 | Bellinger Andrew | sold | -19,851 | 22.95 | -865 | cso & cmo |
2022-11-29 | Dorval Allison | acquired | - | - | 1,875 | chief financial officer |
2022-11-29 | Dorval Allison | sold | -12,243 | 22.1 | -554 | chief financial officer |
2022-11-04 | GV 2017 GP, L.L.C. | sold | -1,512,810 | 31.1386 | -48,583 | - |
2022-11-04 | Yeshwant Krishna | sold | -1,512,810 | 31.1386 | -48,583 | - |
2022-11-04 | Yeshwant Krishna | sold | - | - | -48,583 | - |
2022-11-04 | GV 2017 GP, L.L.C. | sold | -1,512,800 | 31.1386 | -48,583 | - |
2022-11-04 | GV 2017 GP, L.L.C. | sold | - | - | -48,583 | - |
2022-11-03 | GV 2017 GP, L.L.C. | sold | - | - | -49,569 | - |
Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | |||
Collaborations revenue | $ 1,941 | $ 0 | $ 0 |
Operating expenses: | |||
Research and development | 130,095 | 68,202 | 35,371 |
General and administrative | 37,533 | 18,865 | 5,256 |
Total operating expenses | 167,628 | 87,067 | 40,627 |
Loss from operations | (165,687) | (87,067) | (40,627) |
Other income (expense): | |||
Change in fair value of preferred stock tranche liability | 0 | 0 | 2,507 |
Change in fair value of antidilution rights liability | 0 | (25,574) | (5,359) |
Change in fair value of success payment liability | 1,486 | (7,815) | (2,387) |
Interest and other income, net | 6,867 | 142 | 162 |
Total other expense, net | 8,353 | (33,247) | (5,077) |
Loss before provision for income taxes | (157,334) | (120,314) | (45,704) |
Provision for income taxes | 53 | 0 | 0 |
Net loss | $ (157,387) | $ (120,314) | $ (45,704) |
Net loss per common share attributable to common stockholders, basic | $ (2.91) | $ (4.48) | $ (20.31) |
Net loss per common share attributable to common stockholders, diluted | $ (2.91) | $ (4.48) | $ (20.31) |
Weighted-average common shares used in net loss per share attributable to common stockholders, basic | 54,023,653 | 26,872,036 | 2,250,093 |
Weighted-average common shares used in net loss per share attributable to common stockholders, diluted | 54,023,653 | 26,872,036 | 2,250,093 |
Comprehensive Loss: | |||
Net loss | $ (157,387) | $ (120,314) | $ (45,704) |
Other comprehensive loss: | |||
Unrealized loss on marketable securities | (466) | (236) | (1) |
Comprehensive loss | $ (157,853) | $ (120,550) | $ (45,705) |
Consolidated Balance Sheets - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 115,412 | $ 64,330 |
Marketable securities | 439,396 | 296,112 |
Collaboration receivable | 1,012 | 0 |
Prepaid expenses and other current assets | 7,339 | 6,686 |
Total current assets | 563,159 | 367,128 |
Property and equipment, net | 18,778 | 7,224 |
Restricted cash | 4,824 | 5,237 |
Operating lease right-of-use assets | 91,877 | 1,839 |
Other long term assets | 585 | 2,696 |
Total assets | 679,223 | 384,124 |
Current liabilities: | ||
Accounts payable | 2,424 | 7,077 |
Accrued expenses | 20,767 | 12,992 |
Operating lease obligations, current portion | 11,904 | 1,955 |
Total current liabilities | 35,095 | 22,024 |
Long-term lease liability | 70,014 | 0 |
Deferred revenue, non-current | 20,014 | |
Success payment liability | 2,885 | 4,371 |
Other long term liabilities | 283 | 377 |
Total liabilities | 128,291 | 26,772 |
Commitments and contingencies (See Note 7 and 8) | ||
Convertible preferred stock (See Note 10) | 0 | 0 |
Stockholders’ equtiy (deficit): | ||
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued and oustanding | 0 | 0 |
Common stock, $0.001 par value; 200,000,000 and 255,000,000 shares authorized at December 31, 2022 and 2021, respectively, 61,730,816 and 48,511,735 shares issued at December 31, 2022 and 2021, respectively; 61,730,816 and 48,511,735 shares outstanding at December 31, 2022 and 2021, respectively | 62 | 49 |
Additional paid-in capital | 895,801 | 544,381 |
Accumulated other comprehensive (loss) income | (694) | (228) |
Accumulated deficit | (344,237) | (186,850) |
Total stockholders’ equity (deficit) | 550,932 | 357,352 |
Total liabilities, and stockholders' equity | $ 679,223 | $ 384,124 |